Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
| Image |  |
|---|---|
| Description | scientific article published in August 2013 |
| Author/s |
author: Steve Chan Ian Ellis Paul M Moseley Srinivasan Madhusudan |
| Publication date | August 1, 2013 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |